Cybrexa Therapeutics Advances Peptide-Drug Conjugate CBX-12 in Platinum-Resistant Ovarian Cancer After Phase 1 Completion
Cybrexa Therapeutics' CBX-12, a 26-amino-acid pH-targeted peptide-drug conjugate that delivers a topoisomerase-1 inhibitor selectively to the acidic tumor microenvironment, completed Phase 1 in September 2024 and has moved into Phase 2 for platinum-resistant ovarian cancer. The peptide-drug conjugate field continues to broaden beyond the bicyclic-peptide and FAP-activated approaches already covered at ASCO, with smaller direct-acting peptide carriers gaining traction.